ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1830

A Novel Population Care Model in Rheumatoid Arthritis – Significant Improvement in Quality and Reduction in Cost of Care

Eric D. Newman1, William T. Ayoub2, David M. Pugliese3, Chelsea Cedeno4, Jason Brown5, Thomas M. Harrington6, Thomas P. Olenginski6, Androniki Bili7, Alfred E. Denio6, Lisa L. Schroeder7, Dennis Torretti7, Tarun Sharma7, Lyudmila Kirillova7, Susan Mathew7, Jonida Cote7, Brian Oppermann2, Cynthia Sullivan2, Shantanu Bishwal8, Brian DelVecchio3 and Howard Aylward9, 1Department of Rheumatology, Geisinger Health System, Danville, PA, 2Rheumatology, Geisinger Health System, State College, PA, 3Rheumatology, Geisinger Health System, Wilkes-Barre, PA, 4Division of Medicine, Geisinger Medical Center, Geisinger Health System, Danville, PA, 5Henry Hood Center for Clinical Research, Geisinger Health System, Danville, PA, 6Dept of Rheumatology, Geisinger Health System, Danville, PA, 7Rheumatology, Geisinger Health System, Danville, PA, 8Rheumatology, Geisinger Health System, Wilkes Barre, PA, 9Geisinger Health System, State College, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cost containment, EHR best practices, quality improvement, quality measures and quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Quality of Care

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Rheumatoid arthritis (RA) is a common chronic disease with significant morbidity, mortality, and cost.  To optimize care for RA patients, we developed a novel value-based population care model – AIM FARTHER (Attribution, Integration, Measurement, Finances, And Reporting of THERapies).  AIM FARTHER was designed to improve quality and reduce cost of RA care.

Methods:   The AIM FARTHER model was designed and implemented for all RA patients cared for by the 17 rheumatologists within our health system (n=~2,300 patients). Components included 1) registry development; 2) defining roles and attribution; 3) integration of primary and specialty care; 4) strategic approach to RA care; 5) RA quality measure bundle development; 6) task management and performance reporting; and 7) a new financial/incentive model.  The RA quality bundle included 8 measures – RA on DMARD (Disease Modifying Anti-Rheumatic Drug), Active RA on DMARD, RA with CDAI (Clinical Disease Activity Index), RA at low disease activity, TB testing if on biologic, Influenza vaccination, Pneumococcal vaccination, and LDL (low density lipoprotein) checked.  These measures were collected electronically, providing the analytics for a patient scorecard (Figure 1).  The scorecard was used to close care gaps, rolled up into provider and department performance reports, and shared transparently.  Analysis of AIM FARTHER included quality (individual measures and “all or none” bundle score) and cost (biologic de-escalation savings).

Results:   AIM FARTHER was implemented August 2012 (2,150 RA patients) with 22 month follow-up (2,378 RA patients).  Significant improvement was noted in all quality measures except active RA on DMARD (92% to 93%)(Figure 2).  Final values were RA on DMARD 90%, RA with CDAI 84%, RA at low disease activity 53%, TB testing on biologic 93%, Influenza vaccine 75%, Pneumococcal vaccine 72%, and LDL checked 95%.  The all or none bundle improved from 22% to 40% (40% of the 2,378 RA patients had achieved 100% of their applicable quality measures).  Cost savings from biologic de-escalation were $720,000 for 2013 with projected savings estimate of $1.2 million for 2014.

Conclusion:   AIM FARTHER is a novel care model employing provider engagement, process redesign, measurement, and information technology to provide optimal care for patients with RA. AIM FARTHER showed significant improvement in quality measures and reduction in cost of care for a population of over 2,300 RA patients.  Additionally, it supports the pivotal role that rheumatology can play in the systematic care of patients with RA.

 


Disclosure:

E. D. Newman,
None;

W. T. Ayoub,
None;

D. M. Pugliese,
None;

C. Cedeno,
None;

J. Brown,
None;

T. M. Harrington,
None;

T. P. Olenginski,
None;

A. Bili,
None;

A. E. Denio,
None;

L. L. Schroeder,
None;

D. Torretti,
None;

T. Sharma,
None;

L. Kirillova,
None;

S. Mathew,
None;

J. Cote,
None;

B. Oppermann,
None;

C. Sullivan,
None;

S. Bishwal,
None;

B. DelVecchio,
None;

H. Aylward,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-population-care-model-in-rheumatoid-arthritis-significant-improvement-in-quality-and-reduction-in-cost-of-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology